Market Research Logo

IVD in China


Attention: There is an updated edition available for this report.

This report, IVD in China represents Kalorama's complete analysis on the Chinese IVD market.  The report provides an introduction to the healthcare system in China, the results of recent reform efforts, and issues and trends.  Regional breakouts of the Chinese system are provided.  The report describes the role that out-of-pocket expenditures and private concerns play in the delivery of healthcare in the nation.
 
The modern Chinese healthcare market was borne of and continues to be guided by the progressive intentions of the central government of the People’s Republic of China. The government’s liberalization of the mainland Chinese economy beginning in the 1970s was accompanied by the elimination of long-standing and costly healthcare schemes and other social safety nets.   IVD is an important part of the healthcare system and the industry has been impacted by the changes described in this report.

As part of its analysis, Market Size and Forecasts for Key IVD Markets  including:
•    Clinical Chemistry
•    Microbiology, ID/AST and Molecular
•    Point of Care Testing
•    Immunoassays
•    Urinalysis
•    Molecular Testing  
•    Coagulation  
•    Histology  
•    Hematology  
•    Blood Testing and Typing  
•    Flow Cytometry  

More affluent Chinese were also introduced to health problems associated with the adoption of new lifestyles associated with urbanization and greater discretionary income in opened consumer markets. Rising life expectancy and the one-child policy have accelerated demographic aging in China, representing another major long-term trend guiding increased healthcare demand. In short, China is confronted by a host of continuing and novel structural challenges to the accessibility and provision of modern healthcare for its demographically diverse, geographically dispersed, and economically stratified populace.

While private sector hospitals and clinics’ role in the formation of the contemporary Chinese healthcare sector is notable, China’s central, regional and local governments have been the greatest factor behind exceptional growth in the Chinese healthcare market. The central government has initiated pivotal investment strategies with public funds to drive infrastructural expansion, mediated relations between multinational companies and domestic industry, and controlled access to domestic distribution channels and Chinese patients. Central planning, other regulatory controls and regional investment on the part of provincial and local governments have also guided extraordinary growth in healthcare markets that include leading domestic markets in Beijing, Shanghai, Guangzhou, Shenzhen and Hong Kong as well as newly-developed and booming regional markets in China’s growing domestic economy.

The report provides coverage of key Issues and Trends in the market, and details competitors in the IVD industry.  As part of its coverage, the following companies are profiled:


•    Affymetrix, Inc.
•    Axis-Shield plc
•    Biohit Oy
•    Hologic, Inc.
•    IRIS International, Inc.
•    Life Technologies Corporation
•    Luminex Corporation
•    MedMira
•    Novartis Diagnostics
•    PerkinElmer
•    Promega Corporation
•    Phadia AB
•    QIAGEN N.V.
•    Siemens Healthcare Diagnostics
•    SuperNova Diagnostics, Inc.
•    Chinese IVD Companies – Recent Activity
•    CapitalBio Corporation
•    Caretium Medical Instruments
•    Chemtron Biotech Co. Ltd.
•    China Health Labs & Diagnostics Ltd.
•    Daan Gene Co. Ltd.
•    Shanghai Fosun Pharmaceutical Co. Ltd.
•    Hai Kang Life Corporation
•    Beijing Leadman Biochemistry Co. Ltd.
•    Mindray Medical International Ltd.



  • Executive Summary
    • INTRODUCTION
    • CHINA IN CONTEXT -ADEVELOPING ECONOMY WITH FIRST-WORLD PROBLEMS
      • Demographic Aging
      • Disease Drivers
      • Infectious Disease Threats
    • IVDMARKET IN CHINA
      • Table IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other)
      • Table BRIC IVD Markets by Country, 2012-2017 ($ millions)
    • CHINESE HEALTHCARE REFORM AND HOSPITAL INFRASTRUCTURE
    • MARKET BARRIERS -REGULATION, POLICY AND DISTRIBUTION
      • Regulation and Policy Challenges for International Companies
      • Distribution in China
    • MAJOR FINDINGS OF THE REPORT
  • Introduction to Health Care and Diagnostics in the Developing World - China in Context
    • BACKGROUND
    • POPULATION TRENDS AND DISEASE DEMOGRAPHICS
      • Table Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050)
      • Table Selected Worldwide Disease Statistics
    • DISEASE TRENDS
      • Diabetes
      • Cancer
      • Allergy
      • Cardiovascular Disease
      • Emerging Viruses and Diseases
    • MARKET SEGMENT OPPORTUNITIES
      • Point-of-Care (POC) Testing
      • Clinical Labs
        • Table Clinical Lab Counts and Lab Automation Penetration in BRIC Countries
      • Research and High Technology
    • THE FUTURE OF CHINESE ECONOMIC GROWTH
    • BRICMETRICS -CHINESE IVDMARKET IN CONTEXT
      • Available Markets - Urban Populations in BRIC Countries
        • Table Available (Urban) Market Development in BRIC Countries (2003-2012)
      • Paying for Healthcare - Government Expenditures and the Culture of Spending
        • Table Government and Total Health Expenditures in BRIC and Comparison Countries (% of GDP and $ Billions)
        • Table Growth Rates of Government and Total Healthcare Expenditures and Real GDP (BRIC and Comparison Countries; 2003-2012)
      • Healthcare Capacities in BRIC Nations - A Work in Progress
        • Table Healthcare System Capacities - BRIC and Comparison Countries
    • IVD SPENDING
      • Table Per Capita IVD Expenditures and IVD Markets by Country, 2012
      • Table BRIC IVD Markets by Country, 2012-2017 ($ millions)
    • WILL CHINA CAPTURE THE IVD INDUSTRY?
      • Table Selected Made-in-China Lab Supplies
  • China IVD Market Size and SWOT Analysis
    • INTRODUCTION
    • THEMARKET
      • Table IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other)
    • STRENGTHS -AVAILABLE MARKET, INFRASTRUCTURE EXPANSION AND CHALLENGING DISEASE BURDENS
    • WEAKNESSES - FACTORS THAT OFFER BARRIERS TO MARKET SUCCESS AND ENTRY
      • Insurance
        • Table Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (% of Total Expenditures)
      • Regulation - Product Approval and Clinical Trials
      • Regulation - Healthcare Service Cost Controls
      • Distribution Challenges
    • OPPORTUNITIES -RURAL HEALTHCARE AND TECHNOLOGY PARTNERSHIPS
    • THREATS -DOMESTIC COMPETITION AND GOVERNMENT POLICY
  • Industry and Company Activity in China
    • INTRODUCTION
      • Table Leading IVD Companies in China
      • Table Other IVD Companies in China
      • Affymetrix, Inc.
      • Axis-Shield plc
      • Biohit Oy
      • Hologic, Inc.
      • IRIS International, Inc.
      • Life Technologies Corporation
      • Luminex Corporation
      • MedMira
      • Novartis Diagnostics
      • PerkinElmer
      • Promega Corporation
      • Phadia AB
      • QIAGEN N.V.
      • Siemens Healthcare Diagnostics
      • SuperNova Diagnostics, Inc.
    • CHINESE IVD COMPANIES -RECENT ACTIVITY
      • CapitalBio Corporation
      • Caretium Medical Instruments
      • Chemtron Biotech Co. Ltd.
      • China Health Labs & Diagnostics Ltd.
      • Daan Gene Co. Ltd.
      • Shanghai Fosun Pharmaceutical Co. Ltd.
      • Hai Kang Life Corporation
      • Shanghai Kehua Bio-engineering
      • Beijing Leadman Biochemistry Co. Ltd.
      • Mindray Medical International Ltd.
        • Table Chinese IVD Companies at the AACC's 2012 LabExpo (Contact Information and Product Summary)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report